Dynavox Group (DYVOX) investor relations material

Executive summary

• Revenue grew 15% year-over-year in Q1 2026 (FX-adjusted), with organic growth at 11% and acquisitions contributing 3%.

• EBIT increased by 35% to SEK 57 million, with an EBIT margin of 9.8% compared to 7.3% last year.

• Cash flow after investments more than doubled to SEK 56 million year-over-year.

• North America faced temporary weather-related disruptions, but March rebounded to historic growth levels and deferred sales are expected to be regained.

• Acquisition of Italian reseller SR Labs Healthcare completed in April, expanding direct market presence.

Financial highlights

• Q1 revenue: SEK 588 million, up 15% year-over-year (FX-adjusted); reported growth 1%.

• Gross margin: 67%, down from 68–69% last year, mainly due to higher component costs and staffing.

• EBIT: SEK 57 million, EBIT margin 9.8%, up from 7.3% last year.

• Basic EPS: SEK 0.36, up from SEK 0.23 last year.

• Cash at hand: SEK 243 million; net debt: SEK 865 million; net debt/EBITDA: 1.7x.

Outlook and guidance

• Full-year financial targets reiterated: 20% annual revenue growth (FX-adjusted, including acquisitions) and EBIT margin to reach/exceed 15%.

• Deferred Q1 sales in North America expected to be regained later in the year; underlying demand remains robust.

• Currency headwinds have decreased entering Q2, with SEK/USD fluctuations stabilizing.

• No material macroeconomic or policy impacts observed to date.